PharmaCyte Biotech (PMCB) Treasury Shares (2012 - 2026)

PharmaCyte Biotech (PMCB) has reported Treasury Shares for 5 consecutive years, with $45.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Treasury Shares rose 0.9% year-over-year to $45.0 million; the TTM figure through Apr 2026 stood at $45.0 million (up 0.9% YoY), while the FY2026 annual figure was $45.0 million, up 0.9% from the prior year.
• Treasury Shares steadied at $45.0 million in Q2 2026 per PMCB's latest filing, from $45.0 million in the prior quarter.
• Across five years, Treasury Shares topped out at $15.3 million in Q1 2026 and bottomed at -$13.2 million in Q1 2024.
• Historically, Treasury Shares has averaged $5.8 million across 5 years, with a median of $9.2 million in 2023.
• Annual changes were most pronounced in 2023 — Treasury Shares jumped 1813.96% — and 2026, when it grew 0.9%.
• PharmaCyte Biotech's Treasury Shares stood at $5.5 million in 2022, then surged by 638.68% to $40.4 million in 2023, then rose by 9.29% to $44.2 million in 2024, then grew by 0.91% to $44.6 million in 2025, then climbed by 0.9% to $45.0 million in 2026.
• Business Quant data shows PMCB's Treasury Shares at $45.0 million in Q2 2026, $45.0 million in Q1 2026, and $44.6 million in Q4 2025.